Journal Mobile Options
Table of Contents
Vol. 73, No. 4, 2006
Issue release date: June 2006
Section title: Clinical Investigations
Respiration 2006;73:420–427
(DOI:10.1159/000089655)

The Effect of Tiotropium on Hyperinflation and Exercise Capacity in Chronic Obstructive Pulmonary Disease

Verkindre C. · Bart F. · Aguilaniu B. · Fortin F. · Guérin J.-C. · Le Merre C. · Iacono P. · Huchon G.
aCentre Hospitalier Germon et Gauthier, Béthune, bHYLAB Laboratoire de Physiologie Clinique, Grenoble, cCLEFAR, Clinique de la Louvière, Lille, dHôpital Croix Rousse, Lyon, eCHR, Service de Pneumologie, Médecine Interne A, Nîmes, fBoehringer Ingelheim France, Reims, et gPneumologie et Réanimation Hôtel-Dieu, Paris, France

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Clinical Investigations

Published online: 7/5/2006

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 3

ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)

For additional information: http://www.karger.com/RES

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation, which results in the progressive development of dyspnea and exercise limitation. Objective and Methods: To compare the effect of tiotropium with placebo on forced vital capacity (FVC) in patients with moderate-to-severe COPD and lung hyperinflation, using exercise endurance, dyspnea and health-related quality of life (HRQoL) as secondary endpoints. One hundred patients were randomized to receive either tiotropium 18 µg once daily or placebo for 12 weeks. Results: Trough (predose) FVC was significantly improved with tiotropium compared to placebo on day 42 (0.27 ± 0.08 liters) and 84 (0.20 ± 0.08 liters; p < 0.05 for both). Trough inspiratory capacity (IC) was also significantly improved with tiotropium compared to placebo on day 42 (0.16 ± 0.07 liters) and 84 (0.15 ± 0.07 liters; p < 0.05 for both). Tiotropium increased the mean distance walked during the shuttle walking test by 33 ± 12 (day 42) and 36 ± 14 m (day 84) compared to placebo (p < 0.05 for both). On day 84, 59% of the patients in the tiotropium group and 35% of the patients in the placebo group had significant and clinically meaningful improvements in the St. George’s Respiratory Questionnaire total score (p < 0.05). Numerical decreases in the focal score in the Transition Dyspnea Index in patients receiving tiotropium versus placebo suggest that tiotropium also improved dyspnea during activities of daily living. Conclusion: Tiotropium 18 µg once daily reduced hyperinflation with consequent improvements in walking distance and HRQoL in patients with COPD and lung hyperinflation.


  

Author Contacts

Gerard Huchon
Pneumologie et Réanimation Hôtel-Dieu
1 Place du Parvis Notre-Dame
FR–75181 Paris Cedex 4 (France)
Tel. +33 1 4234 8482, Fax +33 1 4234 8448, E-Mail gerard.huchon@htd.ap-hop-paris.fr

  

Article Information

Lead Investigators and Participating Centers: B. Aguilaniu, UCPX, Laboratoire de Physiopathologie de l’Exercice, Grenoble; F. Bart, Centre Hospitalier Germon et Gauthier, Béthune; D. Caillaud, CHU, Hôpital Gabriel Montpied, Service de Pneumologie, Clermont- Ferrand; F. Fortin, CLEFAR, Clinique de la Louvière, Lille; H. Guenard, Centre François Magendi, Hôpital de Haut Lévêque, Pessac; J.-C. Guérin, Hôpital Croix Rousse, Lyon; C. Le Merre, CHR, Hôpital Gaston Doumergue, Service de Pneumologie, Médecine Interne A, Nîmes; G. Huchon, Pneumologie et Réanimation Hôtel-Dieu, Paris; J.F. Muir, Centre Hospitalier, Bois Guillaume; B. Wallaert, Hôpital A. Calmette, Département de Pneumologie et Immuno-Allergologie, Lille, France.

Received: January 27, 2005
Accepted after revision: July 20, 2005
Published online: November 7, 2005
Number of Print Pages : 8
Number of Figures : 4, Number of Tables : 3, Number of References : 34

  

Publication Details

Respiration (International Journal of Thoracic Medicine)

Vol. 73, No. 4, Year 2006 (Cover Date: June 2006)

Journal Editor: Bolliger, C.T. (Cape Town)
ISSN: 0025–7931 (print), 1423–0356 (Online)

For additional information: http://www.karger.com/RES


Article / Publication Details

First-Page Preview
Abstract of Clinical Investigations

Published online: 7/5/2006

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 3

ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)

For additional information: http://www.karger.com/RES


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.